Inmunoterapia en cáncer cutáneo no melanoma
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 110 (5) , 353-359
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Novedades en inmunología del melanomaActas Dermo-Sifiliograficas, 2017
- CTLA-4 and PD-1 PathwaysAmerican Journal of Clinical Oncology, 2016
- Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumabEuropean Journal of Cancer, 2015
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJournal of Clinical Oncology, 2015
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathwaysImmunological Reviews, 2008
- PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology, 2001